Hamlet Pharma has participated in a number of recent events, presenting highligts from the promising clinical studies and our future strategy. With this newsletter, we…
Hamlet PharmaMay 24, 2022
This is HAMLET – The movie
(English version)
Watch interview with Catharina Svanborg and Mats Persson at Stockholm Corporate Finance Life Science Day, March 8, 2022 (Swedish)
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision
PDF (Swedish)
PDF (English)
European Union Horizon 2020 – EIC Accelerator Program
Read our Annual Report 20/21 (Swedish)
Read our Q2 Interim Report October-December 2021 (English)
VI FORTSÄTTER MOT FAS III
Tidningen Affärsvärlden skriver i en artikel den 23 maj om Hamlet Pharma och om mig där man presenterar företagets verksamhet och dessutom påstår att jag förutom lön även skulle fakturera stora summor till mig personligen via företaget Linnane Pharma.
Detta är fel!
Jag tydliggör därför och repeterar mitt svar hämtat ur artikeln:
”Jag är anställd och får lön. Jag har inget arvode som styrelseordförande och pengarna till Linnane Pharma går inte till mig utan är kostnader för att täcka användandet av teknologiplattformen. Min sammanlagda lön, både i Hamlet Pharma och SelectImmune Pharma är 110 000 kronor i månaden”.
För att förtydliga ytterligare:
Ersättningen till Linnane Pharma har inget med mig att göra. Det handlar om kostnader för att Hamlet Pharma använder och drar fördelar av teknologiplattformen. Det är i själva verket en gynnsam prenumerationsavgift och en konstruktion för att ha tillgång till denna utvecklingsplattform.
Hamlet Pharma har nu genomgått och klarat de tidiga kliniska faserna i vår läkemedelsutveckling med bland annat forskningsanslag från EU. Det gör att vi är framme vid punkten där vi går mot Fas III för godkännande av berörda myndigheter i Europa och USA.
Vi har gjort det här snabbt och under ett begränsat antal år och mitt under pandemin med alla dess restriktioner. Processen mot godkännanden är i full gång.
Catharina Svanborg
News
Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”) emitterade under 2021 teckningsoptioner av serie TO 3 B och TO 4 B. Varje teckningsoption ger rätt…
Hamlet PharmaMay 24, 2022
Hamlet Pharma enters a new business development phase involving multiple cancer indications and markets. Based on the successful outcomes of our clinical trial program, we…
Hamlet PharmaApril 19, 2022
HAMLET has been featured in a range of articles across the world. See more news
Why clinical trials matter?
The strategic goal of Hamlet Pharma is to develop novel cancer treatments for patients who currently lack therapeutic options. Conducting clinical trials is crucial to reach primary goals such as evaluating the therapeutic window for HAMLET in bladder cancer. We also aim to gain new insights that facilitate the drug development for Alpha1H and the diversification of our activities to include other indications.
The Phase I/II Clinical Trial In Patients With Bladder Cancer
Development Plan Achievements
The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. Our aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.
Outcome of the Phase I/II trial in patients with bladder cancer.
Hamlet Pharma Ltd. is making great progress and has just concluded the first part of a clinical trial in patients with bladder cancer. Drug development often takes many years, due to complex development and approval processes. Based on our extensive prior experience, the drug candidate, Alpha1H, has passed a number of important milestones in a relatively short time and with moderate cost.
The results of the clinical trial will be announced shortly.
The HAMLET Story
A research group in Lund, led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells.
Since the discovery, the research team has successfully worked to characterize the HAMLET structure, its mechanisms and treatment effects in animal models and in patients. HAMLET´s tumor killing abilities have since the discovery been confirmed by several international research groups working on different aspects of HAMLET.
The research results have been published in prestigious journals like The New England Journal of Medicine, GUT, Nature Reviews Gastroenterology and PNAS (Proceedings of the National Academy of Science, USA).
About Hamlet PharmaHAMLET offers a unique vision for the improvement of cancer-specific therapies.
HAMLET is a tumoricidal protein-lipid complex, formed by two GRAS (generally regarded as safe) molecules present in human milk. The novel therapeutic entity HAMLET is formed when the human milk protein alpha-lactalbumin undergoes a conformational change and binds to oleic acid.
HAMLET kills cancer cells of different origins (more than 40 different types of cancer cells) and is active in multiple oncology and dermatology indications.
HAMLET has been shown to be safe and effective in man as demonstrated in two proof-of-concept human clinical trials. Convincing therapeutic efficacy was demonstrated in a topical skin papilloma study and in patients with bladder cancer, HAMLET induced rapid shedding of dead tumor cells and a reduction in tumor size after one week. Therapeutic effects have also been demonstrated in several animal cancer models, including glioblastoma, bladder cancer and most recently, colon cancer.
A large scale, GMP certified manufacturing process is in place.
HAMLET does not kill healthy differentiated cells in the laboratory and has not shown toxicity against healthy tissues in animal models or clinical studies. Instead, HAMLET accumulates specifically in tumor tissues in these models.
HAMLET addresses serious unmet medical needs in multiple large oncology markets, including colon cancer, bladder cancer, cervix cancer and brain tumors (primary or metastatic) and may qualify for Orphan Disease and Fast Track Status with the FDA.
Partnering/Licensing: Oncology is the top therapeutic area for licensing and partnering by pharmaceutical companies. Efficient and suitable strategies for the immediate financing of HAMLET’s development and for future partnering are needed.
Remarkably, HAMLET identifies conserved unifying characteristics of cancer cells. HAMLET acts through a broad attack on membrane constituents and multiple intracellular targets with conserved structural motifs. These mechanisms differ from molecules targeted by most traditional monoclonal antibody or small molecule-based therapeutics.
Intellectual Property includes composition of matter, manufacturing and use patents for HAMLET as well as second-generation HAMLET molecules and manufacturing procedures. Patents have been granted in the US and Europe.
Selective and efficient tumor cell removal would present a unique basis for cancer therapy. HAMLET has shown remarkable efficiency and selectivity in several cancer models. We therefore aim to develop HAMLET by producing large quantities under industrial conditions, by extending the clinical trials and by defining HAMLET to fulfill the regulatory and toxicological requirements for a marketable drug.